Group items tagged

Mozambique is at a critical junction of controlling its HIV/AIDS epidemic in order to meet The Joint United Nations Programme on HIV/AIDS (UNAIDS) goal of 90-90-90 by 2020 and 95-95-95 by 2030. Reaching these goals not only requires robust clinical interventions, but simultaneously requires addressing social, cultural, and legal barriers that inhibit equal access to health services for all people living with and affected by HIV. This requires not only the training of those at a local level who interact with people living with HIV/AIDS (PLHIV) or other vulnerable populations but also building the capacity of civil society organizations that can assist with improving uptake of HIV services as well as improving retention and linkages. This NOFO will increase the availability, accessibility, acceptability, and quality of HIV services provided in health facilities or community level by implementing innovative activities that reduce stigma and discrimination, increase retention and linkages of HIV and TB services, improve health facilities’ redress mechanisms, optimize care for HIV and TB patients, and improve patient rights and access to quality services for PLHIV.

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.

The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.

The Air Force Office of Scientific Research "we, us, our, or AFOSR" manages the basic research investment for the U.S. Air Force. As a part of the Air Force Research Laboratory (AFRL), our technical experts discover, shape, and champion research within the Air Force Research Laboratory, universities, and industry laboratories to ensure the transition of research results to support U.S. Air Force needs. Using a carefully balanced research portfolio, our research managers seek to foster revolutionary scientific breakthroughs enabling the Air Force and U.S. industry to produce world-class, militarily significant, and commercially valuable products. Our focus is on research areas that offer significant and comprehensive benefits to our national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific Branches:  Engineering and Information Sciences (RTA) Physical and Biological Sciences (RTB)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCIs Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.

Computational neuroscience provides a theoretical foundation and a rich set of technical approaches for understanding complex neurobiological systems, building on the theory, methods, and findings of computer science, neuroscience, and numerous other disciplines. Through the CRCNS program, the National Science Foundation (NSF), the National Institutes of Health (NIH), the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF), the French National Research Agency (Agence Nationale de la Recherche, ANR), the United States-Israel Binational Science Foundation (BSF), and Japan's National Institute of Information and Communications Technology (NICT) support collaborative activities that will advance the understanding of nervous system structure and function, mechanisms underlying nervous system disorders, and computational strategies used by the nervous system.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field.

: The Division of Integrative Organismal Systems (IOS) continues to support the Enabling Discovery through GEnomic Tools (EDGE) program, previously a component of the IOS Core Programs solicitation (NSF 16-505). EDGE is designed to provide support for research addressing current impediments to research progress in organismal biology. In particular, the ability to directly test gene function is essential to improve understanding of the genomes-to-phenomes relationship, an area relevant to Understanding the Rules of Life, one of 10 Big Ideas for future NSF investment (www.nsf.gov/about/congress/reports/nsf_big_ideas.pdf). EDGE projects should focus on development of functional genomic tools, approaches, and associated infrastructure to enable direct tests of hypotheses about gene function in diverse organisms for which such tools and infrastructure are presently unavailable. EDGE proposals must include training and rapid dissemination plans enabling larger communities of investigators to utilize the newly-developed tools, thereby catalyzing an increase in the capacity of research communities to test cause-and-effect hypotheses about genes and phenotypes in organisms for which such tools and infrastructure are presently lacking.

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .

The purpose of this funding opportunity announcement (FOA) is to support non-commercial lab-to-user dissemination of novel, reliable imaging and bioengineering technologies, including devices, software, methods, chemical agents, etc. Proposed technologies should have been prototyped, validated, and are potentially highly impactful to the research community. However, their beyond-the-lab dissemination via commercialization or industry partnership is not anticipated. Projects should focus on transforming functioning prototypes to usable tools and delivering them to end users for high-quality research in a reliable manner. Related activities may include, but are not limited to, quality control, scale-up production, user training, and technical improvements that are within the scope of the prototyped technology and limited to applying proven techniques or existing resources. Projects that involve clinical trials, commercialization, academic-industry partnership, or service using existing equipment are not responsive to this FOA.

This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in the genetic basis of tolerance may consider FOA (PA-18-660).

The SBIR Road Tour will visit Ohio State University on June 20. The SBIR Road Tour is a national outreach effort to convey the non-dilutive technology funding opportunity provided through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Federal and State Program Managers representing the $2.5 billion in early stage funding have been invited to attend a series of events alongside technology entrepreneurs and innovation supporters from across the United States.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).

The Department of Defense (DoD) announces the Fiscal Year 2019 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. We refer to eligible institutions of higher education as universities in the rest of this announcement. DURIP is part of the University Research Initiative (URI).

This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials.

This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. U01 awardees will be expected to attend annual Program Progress/Steering Committee meetings and present progress to fellow awardees and to NIAID program staff. The goal of the meetings is to facilitate collaborations between funded investigators and to accelerate development of mechanistic models that incorporate the collective findings of this program. Advances in our understanding of these Fc-dependent killing mechanisms will inform more efficient design and optimization of ablative antibody therapeutics and may also inform design of vaccines that preferentially elicit ADCC- or ADCP-efficient antibody responses. This FOA uses the U01 grant mechanism, while the companion FOA, PA-19-xxx, uses the R21 mechanism. High risk/high reward projects with limited preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

The U.S. Army Medical Research and Materiel Command's mission is to responsively and responsibly create, develop, deliver, and sustain medical capabilities for the Warfighter. The AIMM initiative was created to accelerate transformational biomedical research for our Armed Forces and Nation. The mission of the AIMM initiative is to encourage, identify, and enable innovative research that leads to cross-cutting solutions to military health threats. The AIMM Research Award is intended to support highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine. AIMM initiative funding supports novel research concepts and other efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs.

The Howard Hughes Medical Institute (HHMI) in Chevy Chase, Maryland, is inviting applications for the third round of its Inclusive Excellence Initiative (IE3), which is designed to promote diversity and inclusion in science education. The program challenges colleges and universities to work with faculty to examine and change campus cultures so that a diverse group of students feel included in science. More than 1,400 institutions are eligible to compete, and HHMI expects to award grants to up to 30 more schools, with $1 million provided to each over five years.